Evidence map›Paper›PMID 32335675›Full record

ArticleThe Journal of antimicrobial chemotherapy2020

HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design.

Ángel Bayón-Gil, Maria C Puertas, Víctor Urrea, Lucía Bailón, Sara Morón-López, Patricia Cobarsí, Christian Brander, Beatriz Mothe, Javier Martinez-Picado

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ángel Bayón-GilIrsiCaixa AIDS Research Institute, Badalona, Spain.
Maria C PuertasIrsiCaixa AIDS Research Institute, Badalona, Spain.
Víctor UrreaIrsiCaixa AIDS Research Institute, Badalona, Spain.
Lucía BailónFight AIDS Foundation (FLS), Infectious Disease Service, Germans Trias i Pujol University Hospital, Badalona, Spain.
Sara Morón-LópezIrsiCaixa AIDS Research Institute, Badalona, Spain.
Patricia CobarsíFight AIDS Foundation (FLS), Infectious Disease Service, Germans Trias i Pujol University Hospital, Badalona, Spain.
Christian BranderIrsiCaixa AIDS Research Institute, Badalona, Spain.
Beatriz MotheIrsiCaixa AIDS Research Institute, Badalona, Spain.
Javier Martinez-PicadoIrsiCaixa AIDS Research Institute, Badalona, Spain.
IrsiCaixa · ESFundació Lluita contra les Infeccions · ESInstitució Catalana de Recerca i Estudis Avançats · ESUniversitat de Vic - Universitat Central de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInitiation of combination antiretroviral therapy (cART) soon after HIV-1 infection limits the establishment of viral reservoirs. Thus, early treated individuals are preferred candidates to evaluate novel viral remission strategies. However, their cART-dependent HIV-1 DNA decay dynamics are still poorly defined. This can hamper the design and interpretation of results from clinical trials intended to further reduce viral reservoirs.

objectivesTo clarify the duration of cART needed for the HIV-1 reservoir to be stabilized in early treated individuals.

methodsWe characterized the longitudinal decline of total HIV-1 DNA levels by droplet digital PCR in 21 individuals initiating cART within 6 months after estimated HIV-1 acquisition. Measurements were taken at cART initiation, after 6 months and annually until Year 4. Correlations between virological and clinical parameters were statistically analysed. Statistical modelling was performed applying a mixed-effects model.

resultsTotal HIV-1 DNA experienced a median overall decrease of 1.43 log10 units (IQR = 1.17-1.69) throughout the 4 years of follow-up. Baseline levels for total HIV-1 DNA, viral load, absolute CD4+ T cell count and CD4+/CD8+ ratio correlate with final HIV-1 DNA measurements (R2 = 0.68, P < 0.001; R2 = 0.54, P = 0.012; R2 = -0.47, P = 0.031; and R2 = -0.59, P = 0.0046, respectively). Statistical modelling shows that after 2 years on cART the viral reservoir had reached a set point.

conclusionsA waiting period of 2 years on cART should be considered when designing interventions aiming to impact latent HIV-1 reservoir levels and viral rebound kinetics after cART discontinuation, in order to facilitate interpretation of results and enhance the chance of viral control.

Indexed as

HIV-1HIV InfectionsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountClinical Trials as TopicDNA, ViralHumansViral LoadVirus LatencyAnti-Retroviral AgentsDNA, Viral

Identifiers

PMID32335675
PMCPMC7366202
OpenAlexW3017939763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.